Clozapine Augmentation for Partial Response: ECT vs. Second Antipsychotic vs. Lamotrigine
Clozapine at an adequate trial and a confirmed therapeutic level still leaves residual voices she cannot ignore. Every augmentation option on the table rests on genuinely thin, competing evidence.
S.N., a 41-year-old woman, spent nearly six years unable to work or live independently before clozapine, cycling between her parents' home and brief stays in supported housing as her prior antipsychotic trials failed one after another. She has been on clozapine for eight months now, titrated to a confirmed therapeutic serum level and tolerated without the severe adverse effects that sometimes force early discontinuation. Her positive symptoms improved substantially in the first three months — she stopped responding aloud to internal stimuli and returned to part-time work at a bakery, her first job in over five years — but for the past several weeks she has plateaued with residual, intermittent auditory hallucinations.
She describes the voices now as quieter but still present most days, clearly distressing to her even though she can now largely function around them, and says she's afraid of losing the bakery job if they get louder again. Her parents, who accompany her to this visit, describe watching her regain a version of independence they hadn't seen in years and are anxious about anything that might unsettle it.
This is the exact population clozapine augmentation strategies exist for, and none of the three most commonly used options rests on strong evidence. Adding a second antipsychotic to clozapine is common in practice despite a limited and inconsistent trial base specifically targeting this kind of partial response. Lamotrigine augmentation has some randomized support but results across trials have been mixed enough that it isn't treated as reliably effective. ECT added to continued clozapine has real evidence in exactly this clozapine-partial-response population and is arguably the best-supported of the three options on the actual data, but carries a burden — anesthesia, a multi-week acute course, cognitive side effects, and the logistics of a working woman getting to and from sessions — that neither of the medication options does.
Augmentation strategy
I'd try lamotrigine first. It's oral, doesn't require anesthesia or missed workdays, and she's already told us directly that keeping her job matters to her. Tiihonen and colleagues' 2009 meta-analysis pooling five placebo-controlled trials found a real, significant benefit for lamotrigine added to clozapine — this isn't a long shot. If it doesn't help, we haven't foreclosed anything.
That meta-analysis is real, but I wouldn't lean on it as cleanly as "a real, significant benefit" suggests. A later reanalysis by Sommer and colleagues, published in 2012, revisited those same five trials and found the entire positive result rested on one outlier study — drop that single trial and the result is no longer statistically significant. In plain terms: the finding isn't fabricated, but it's carried almost entirely by one study, not five converging ones.
ECT has a cleaner signal specifically in this population. Petrides and colleagues' randomized trial, published in the American Journal of Psychiatry in 2015, found fifty percent of clozapine-resistant patients who got ECT added to continued clozapine met response criteria, against none of the patients who stayed on clozapine alone. You said trying lamotrigine first "hasn't foreclosed anything" if it fails — that's true of time, but the usual logic of try-the-easy-option-first isn't obviously right when the easy option is also resting on the shakiest number of the three.
Worth naming honestly: the option neither of you has proposed, a second antipsychotic added to clozapine, is actually the most common thing done in practice, and it's not a safer middle ground than either of your options. Taylor and Smith's 2009 meta-analysis, pooled across ten placebo-controlled trials, showed significant benefit on only one of several outcome measures, with a small effect size — if anything, it's the least-evidenced of the three, common only because it's the most familiar mechanism.
That leaves a real choice between the two of you, not a third option rescuing us from it. Given how directly she's told us what she wants to protect, I'd start lamotrigine now, exactly as you suggested, but tell her plainly what you just told me — that the positive result leans on one study, not five — so her preference is informed rather than reassured past the actual evidence. ECT stays explicitly named as the next step, not an unspoken fallback, if this doesn't hold.
Agreed: lamotrigine augmentation started first, at S.N.'s own stated preference, with the team's honest caveat about mixed evidence documented and discussed with her directly rather than left implicit.
Not agreed: how long to trial lamotrigine before moving to ECT if residual symptoms persist — the psychiatrist favors a longer trial to respect her preference, the pharmacologist favors a shorter one given the weaker evidence base.
S.N. was told plainly that ECT remains the best-evidenced next step if this doesn't work, so that decision doesn't arrive as a surprise escalation later.